Table 1.
Main characteristics of studies included in this meta-analysis.
| SNP | First Author | Ethnicity | Sample size | Cases | Controls | HWE P value | Source of control | Genotyping method | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case | Control | genotypes | allele | genotypes | allele | ||||||||||||
| rs2435357 | TT | CT | CC | T | C | TT | CT | CC | T | C | |||||||
| Zhang 2007 | Asian | 99 | 132 | 57 | 28 | 14 | 142 | 56 | 29 | 62 | 41 | 120 | 144 | 0.544 | H-B | PCR | |
| Arnold 2008 | Europe | 62 | 30 | 12 | 27 | 23 | 51 | 70 | 2 | 14 | 14 | 18 | 42 | 0.542 | H-B | TaqMan | |
| Miao 2010 | Asian | 315 | 352 | 228 | 65 | 22 | 521 | 109 | 62 | 169 | 95 | 293 | 359 | 0.39 | H-B | PCR | |
| Phusantisampan 2012 | Asian | 68 | 120 | 47 | 14 | 7 | 108 | 28 | 31 | 64 | 25 | 126 | 114 | 0.447 | H-B | PCR-RFLP | |
| Prato 2009 | Europe | 22 | 85 | 11 | 6 | 5 | 28 | 16 | 3 | 32 | 50 | 38 | 132 | 0.435 | H-B | PCR | |
| Zhang 2015 | Asian | 135 | 118 | 101 | 31 | 3 | 233 | 37 | 13 | 30 | 16 | 56 | 62 | 0.88 | NS | TaqMan | |
| Gunadi 2016 | Asian | 93 | 136 | 67 | 22 | 4 | 156 | 30 | 27 | 83 | 26 | 137 | 135 | 0.01 | NS | PCR-RFLP | |
| Yang 2017 | Asian | 362 | 1448 | 209 | 126 | 27 | 544 | 180 | 329 | 802 | 317 | 1460 | 1436 | 0.001 | P-B | TaqMan | |
| Li 2017 | Asian | 99 | 114 | 69 | 27 | 3 | 165 | 33 | 19 | 58 | 37 | 96 | 132 | 0.641 | NS | TaqMan | |
| Qian Jiang 2021 | Asian | 120 | 509 | 88 | 30 | 2 | 206 | 34 | 100 | 252 | 157 | 452 | 566 | 0.44 | H-B | Sequenom | |
| Yang Wang 2020 | Asian | 491 | 509 | 320 | 146 | 25 | 786 | 196 | 100 | 252 | 157 | 452 | 566 | yes | H-B | Sequenom | |
| Kristy Iskandar 2022 | Asian | 73 | 60 | 62 | 11 | 0 | 135 | 11 | 20 | 34 | 6 | 74 | 46 | yes | H-B | TaqMan | |
| rs2506030 | AA | AG | GG | A | G | AA | AG | GG | A | G | |||||||
| Gunadi 2019 | Asian | 60 | 122 | 3 | 21 | 36 | 27 | 93 | 15 | 50 | 57 | 80 | 164 | yes | H-B | TaqMan | |
| Qian Jiang 2021 | Asian | 120 | 512 | 3 | 32 | 85 | 38 | 202 | 42 | 205 | 265 | 289 | 735 | 0.44 | H-B | Sequenom | |
| DehuaYang 2017 | Asian | 345 | 1148 | 13 | 111 | 221 | 137 | 553 | 143 | 550 | 755 | 836 | 2060 | yes | H-B | TaqMan | |
| Yang Wang 2020 | Asian | 502 | 513 | 15 | 137 | 346 | 167 | 829 | 42 | 205 | 265 | 289 | 735 | yes | H-B | Sequenom | |
| Qian Jiang 2015 | Epure | 586 | 586 | 109 | 272 | 205 | 490 | 682 | 207 | 273 | 106 | 687 | 485 | yes | NS | TaqMan | |
| Qi Li 2017 | Asian | 99 | 114 | 2 | 20 | 77 | 24 | 174 | 11 | 46 | 57 | 68 | 160 | yes | NS | TaqMan | |
| Zhen Zhang 2015 | Asian | 137 | 59 | 3 | 26 | 108 | 32 | 242 | 5 | 22 | 32 | 32 | 86 | yes | NS | Taqman | |
PCR, polymerase chain reaction restriction; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; H-B, hospital-based; P-B, population-based; NS, not stated; HWE, Hardy–Weinberg equilibrium.